New York State Teachers Retirement System Has $13.83 Million Holdings in Illumina, Inc. $ILMN

New York State Teachers Retirement System boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 145,636 shares of the life sciences company’s stock after purchasing an additional 6,113 shares during the period. New York State Teachers Retirement System’s holdings in Illumina were worth $13,831,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Next Capital Management LLC acquired a new stake in Illumina in the second quarter valued at approximately $341,000. CWM LLC increased its position in Illumina by 112.9% in the 2nd quarter. CWM LLC now owns 76,711 shares of the life sciences company’s stock valued at $7,319,000 after acquiring an additional 40,676 shares during the period. Generali Asset Management SPA SGR lifted its holdings in shares of Illumina by 51.6% during the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after purchasing an additional 7,574 shares during the period. Andra AP fonden increased its holdings in Illumina by 426.3% in the second quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after purchasing an additional 83,017 shares during the period. Finally, Bourgeon Capital Management LLC grew its position in shares of Illumina by 76.4% in the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock valued at $13,538,000 after buying an additional 61,468 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In related news, insider Scott M. Davies sold 323 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Scott Gottlieb purchased 500 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the transaction, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.17% of the company’s stock.

Illumina Stock Performance

Shares of Illumina stock opened at $146.99 on Wednesday. The firm has a market capitalization of $22.46 billion, a P/E ratio of 32.96, a price-to-earnings-growth ratio of 2.42 and a beta of 1.41. The business’s fifty day simple moving average is $131.12 and its 200 day simple moving average is $110.61. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the company earned $1.14 earnings per share. The company’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ILMN. Guggenheim upped their price objective on shares of Illumina from $114.00 to $144.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. JPMorgan Chase & Co. upped their price objective on shares of Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a report on Monday, December 15th. UBS Group increased their target price on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Illumina presently has an average rating of “Hold” and a consensus price target of $122.56.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Company raised FY‑2025 EPS guidance to a narrowed range of 4.760–4.790 (and set Q4 2025 EPS guidance of 1.270–1.300), which upgrades the prior outlook and supports higher near‑term earnings expectations.
• Positive Sentiment: Illumina introduced the “Billion Cell Atlas,” a genome‑wide perturbation dataset intended to accelerate AI‑driven drug discovery — a strategic product that strengthens Illumina’s addressable market in pharma AI and could drive licensing/data‑services revenue. Illumina introduces Billion Cell Atlas
• Positive Sentiment: Media coverage and analyst notes highlight Illumina’s Connected Multiomics platform and a recent chief medical officer appointment, reinforcing execution on higher‑margin, software/data offerings that can lift long‑term valuation multiples. Assessing Illumina (ILMN) Valuation
• Neutral Sentiment: Illumina released preliminary unaudited Q4 and FY‑2025 results ahead of its full report (earnings will be released Feb. 5, 2026), a routine timing/communication step that gives investors early visibility but keeps final numbers pending. Preliminary Unaudited Financial Results
• Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference; the transcript provides detail on strategy and product rollout but did not contain surprise guidance beyond the updated ranges. J.P. Morgan Presentation Transcript
• Negative Sentiment: ARK/ARK Invest trimmed Illumina holdings (reported block sale of roughly $13.3M), a signal that may weigh on sentiment given ARK’s visibility among growth investors. Cathie Wood Sells Meta and Illumina

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.